Universal Clinical Codes & Terminology Search

Oncology (lung) augmentative algorithmic analysis of digitized whole slide imaging for 8 genes (ALK BRAF EGFR ERBB2 MET NTRK1-3 RET ROS1) and KRAS G12C and PD-L1 if performed formalin-fixed paraffin-embedded (FFPE) tissue reported as positive or negative for each biomarker

Repositioning of previously implanted cardiac contractility modulation transvenous electrode (atrial or ventricular lead)

Cardiovascular disease (acute coronary syndrome [ACS]) IL-16 FAS FASLigand HGF CTACK EOTAXIN and MCP-3 by immunoassay combined with age sex family history and personal history of diabetes blood algorithm reported as a 5-year (deleted risk) score for ACS

Relocation of skin pocket for implanted cardiac contractility modulation pulse generator

Infectious agent detection by nucleic acid (DNA) genitourinary pathogens identification of 20 bacterial and fungal organisms including identification of 20 associated antibiotic-resistance genes if performed multiplex amplified probe technique urine

Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis including review and report implantable cardiac contractility modulation system

Rare diseases (constitutional/heritable disorders) whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis nuclear-encoded mitochondrial gene analysis of 335 nuclear genes including sequence changes deletions insertions and copy number variants analysis blood or saliva identification and categorization of mitochondrial disorder-associated genetic variants

Interrogation device evaluation (in person) with analysis review and report includes connection recording and disconnection per patient encounter implantable cardiac contractility modulation system

Oncology (breast) augmentative algorithmic analysis of digitized whole slide imaging of 8 histologic and immunohistochemical features reported as a recurrence score

Destruction of neurofibroma extensive (cutaneous dermal extending into subcutaneous); face head and neck greater than 50 neurofibromas

Neuropsychiatry (eg depression anxiety) genomic sequence analysis panel variant analysis of 13 genes saliva or buccal swab report of each gene phenotype

Destruction of neurofibroma extensive (cutaneous dermal extending into subcutaneous); trunk and extremities extensive greater than 100 neurofibromas

Oncology (urothelial) mRNA expression profiling by real-time quantitative PCR of MDK HOXA13 CDC2 IGFBP5 and CXCR2 in combination with droplet digital PCR (ddPCR) analysis of 6 single-nucleotide polymorphisms (SNPs) genes TERT and FGFR3 urine algorithm reported as a risk score for urothelial carcinoma

Transurethral waterjet ablation of prostate including control of post-operative bleeding including ultrasound guidance complete (vasectomy meatotomy cystourethroscopy urethral calibration and/or dilation and internal urethrotomy are included when performed)

Oncology (colorectal) screening quantitative real-time target and signal amplification of 8 RNA markers (GAPDH SMAD4 ACY1 AREG CDH1 KRAS TNFRSF10B EGLN2) and fecal hemoglobin algorithm reported as a positive or negative for colorectal cancer risk

Oncology (pan-solid tumor) analysis of DNA biomarker response to anti-cancer therapy using cell-free circulating DNA biomarker comparison to a previous baseline pre-treatment cell-free circulating DNA analysis using next-generation sequencing algorithm reported as a quantitative change from baseline including specific alterations if appropriate

Secretory type II phospholipase A2 (sPLA2-IIA)

Psychiatry (eg depression anxiety) genomic analysis panel including variant analysis of 26 genes buccal swab report including metabolizer status and risk of drug toxicity by condition

Insertion or replacement of neurostimulator system for treatment of central sleep apnea; complete system (transvenous placement of right or left stimulation lead sensing lead implantable pulse generator)

Oncology (prostate) exosome-based analysis of 53 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT-qPCR) urine reported as no molecular evidence low- moderate- or elevated-risk of prostate cancer